Paper - WANFANG MED ONLINE

You Position: Home > Paper

Current status and advances of combination therapy for chronic hepatitis

( views:0, downloads:0 )

Author:: No author available

Journal Title:: Chinese Journal of Clinical Infectious Diseases

Issue:: 4

DOI:: 10.3760/cma.j.issn.1674-2397.2017.04.015

Key Word:: 肝炎,乙型,慢性;联合治疗;HBsAg清除;临床治愈;Chronic hepatitis B;Combination therapy;HBsAg clearance;clinical cure

Abstract： Chronic hepatitis B (CHB) is still a global public health problem, resulting in the high risk of decompensated cirrhosis and hepatocellular carcinoma.At present, there are no single available medications that can induce both potent HBV DNA suppression, and high rates of HBeAg and HBsAg clearance.Therefore, there is great interest in developing combination therapies for patients with chronic HBV infection, which can achieve sustained viral suppression and HBsAg negative inversion after a finite course of treatment leading to clinical cure.This article reviews the current status and advances of combination therapy for CHB.

Reference

[1]Edward J. Gane.Future anti-HBV strategies[J].2017,37(S1).
[2].The global burden of liver disease: The major impact of China[J].2014,60(6).
[3]Sarin, Shiv Kumar,Sood, Ajit,Kumar, Manoj,etc.Effect of Lowering HBV DNA Levels by Initial Antiviral Therapy Before Adding Immunomodulator on Treatment of Chronic Hepatitis B.[J].2007,102(1).
[4]Patrick Marcellin,Sang Hoon Ahn,Xiaoli Ma,etc.Combination of Tenofovir Disoproxil Fumarate and Peginterferon α-2a Increases Loss of Hepatitis B Surface Antigen in Patients With Chronic Hepatitis B[J].2016,(1).
[5]Abigail, Fosdick,Jim, Zheng,Stefan, Pflanz,etc.Pharmacokinetic and pharmacodynamic properties of GS-9620, a novel Toll-like receptor 7 agonist, demonstrate interferon-stimulated gene induction without detectable serum interferon at low oral doses.[J].2014,348(1).
[6]Kawada,N.,Enomoto,M.,Tamori,A.,etc.Combination therapy with a nucleos(t)ide analogue and interferon for chronic hepatitis B: Simultaneous or sequential[J].2013,48(9).
[7]Chi, Heng,Hansen, Bettina E.,Guo, Simin,etc.Pegylated Interferon Alfa-2b Add-on Treatment in Hepatitis B Virus Envelope Antigen-Positive Chronic Hepatitis B Patients Treated with Nucleos(t) ide Analogue: A Randomized, Controlled Trial (PEGON)[J].2017,215(7).
[8]de Man RA,van Zonneveld M,Akarca US,etc.Peg-interferon improves liver histology in patients with HBeAg-positive chronic hepatitis B: no additional benefit of combination with lamivudine.[J].2006,26(4).
[9]Soo Ryang Kim,Masaru Enomoto,Susumu Shiomi,etc.Entecavir and interferon-α sequential therapy in Japanese patients with hepatitis B e antigen-positive chronic hepatitis B.[J].2013,48(3).
[10]Yin-Chen, Wang,Sien-Sing, Yang,Chien-Wei, Su,etc.Predictors of response to pegylated interferon in chronic hepatitis B: a real-world hospital-based analysis.[J].2016.
[11]Pietro Lampertico,Mauro Viganò,Elena Manenti,etc.Low Resistance to Adefovir Combined With Lamivudine: A 3-Year Study of 145 Lamivudine-Resistant Hepatitis B Patients[J].2007,133(5).
[12]Wei, Wei,Qinmei, Wu,Jialing, Zhou,etc.A Better Antiviral Efficacy Found in Nucleos(t)ide Analog (NA) Combinations with Interferon Therapy than NA Monotherapy for HBeAg Positive Chronic Hepatitis B: A Meta-Analysis.[J].2015,12(8).
[13]Schweitzer, Aparna,Horn, Johannes,Mikolajczyk, Rafael T.,etc.Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013[J].2015,386(10003).
[14]Michelle Martinot-Peignoux,Martine Lapalus,Tarik Asselah,etc.HBsAg quantification: useful for monitoring natural history and treatment outcome[J].2014,34(Supplement).
[15]Hiasa, Yoichi,Jahan, Munira,Akbar, Sheikh Mohammad Fazle,etc.Novel insights into immunotherapy for hepatitis B patients[J].2016,10(2).
[16]Invernizzi, F.,Vigano, M.,Grossi, G.,etc.Review article: the potential of interferon and nucleos(t)ide analogue combination therapy in chronic hepatitis B infection[J].2016,44(7).
[17]Sun,J.,Xie,Q.,Tan,D.,etc.The 104-week efficacy and safety of telbivudine-based optimization strategy in chronic hepatitis B patients: A randomized, controlled study[J].2014,59(4).
[18]Luis Casado, Jose.Renal and Bone Toxicity with the Use of Tenofovir: Understanding at the End[J].2016,18(2).
[19]Petersen, Jorg,Dandri, Maura.Optimal therapy for chronic hepatitis B: hepatitis B virus combination therapy?[J].2015,35(Suppl.1).
[20]Schall,R.A.,Washington,M.K.,Marcellin,P.,etc.Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: A 5-year open-label follow-up study[J].2013,381(9865).
[21]Vinay, Sundaram,Kris, Kowdley.Management of chronic hepatitis B infection.[J].2015,351.
[22]Chen,E.-Q.,Tang,H..The current status of combination therapy of Chronic Hepatitis B[J].2013,17(15).
[23]Hiramatsu, Naoki,Yamada, Ryoko,Takehara, Tetsuo.The suppressive effect of nucleos(t)ide analogue treatment on the incidence of hepatocellular carcinoma in chronic hepatitis B patients[J].2016,31(3).
[24]Marc, Bourlière,Pascaline, Rabiega,Nathalie, Ganne-Carrie,etc.Effect on HBs antigen clearance of addition of pegylated interferon alfa-2a to nucleos(t)ide analogue therapy versus nucleos(t)ide analogue therapy alone in patients with HBe antigen-negative chronic hepatitis B and sustained undetectable plasma hepatitis[J].2017,2(3).
[25]Brouwer, Willem Pieter,Xie, Qing,Sonneveld, Milan J.,etc.Adding Pegylated Interferon to Entecavir for Hepatitis B e Antigen-Positive Chronic Hepatitis B: A Multicenter Randomized Trial (ARES Study)[J].2015,61(5).
[26].Prediction models of long-term Cirrhosis and hepatocellular carcinoma risk in chronic hepatitis B patients: Risk scores integrating host and virus profiles[J].2013,58(2).
[27]Li, Guo-Jun,Yu, Yi-Qi,Chen, Shao-Long,etc.Sequential Combination Therapy with Pegylated Interferon Leads to Loss of Hepatitis B Surface Antigen and Hepatitis B e Antigen (HBeAg) Seroconversion in HBeAg-Positive Chronic Hepatitis B Patients Receiving Long-Term Entecavir Treatment[J].2015,59(7).
[28]Bircan Kayaaslan,Rahmet Guner.Adverse effects of oral antiviral therapy in chronic hepatitis B[J].2017,(5).